NovaBay Pharmaceuticals, Inc. Research and Development Expense of Revenue

Research and Development Expense of Revenue of NBY for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development Expense of Revenue for the quarter ending September 30, 2022 was 1.07% (a -18.32% decrease compared to previous quarter)
  • Year-over-year quarterly Research and Development Expense of Revenue increased by 256.67%
  • Annual Research and Development Expense of Revenue for 2021 was 0.52% (a -81.88% decrease from previous year)
  • Annual Research and Development Expense of Revenue for 2020 was 2.87% (a 2.87% increase from previous year)
  • Annual Research and Development Expense of Revenue for 2019 was 2.79% (a 34.78% increase from previous year)
  • Twelve month Research and Development Expense of Revenue ending September 30, 2022 was 0.96% (a 12.94% increase compared to previous quarter)
  • Twelve month trailing Research and Development Expense of Revenue increased by 84.62% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
0.96% 0.85% 0.72% 0.52%
Visit stockrow.com/NBY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development Expense of Revenue of NovaBay Pharmaceuticals, Inc.

Most recent Research and Development Expense of Revenueof NBY including historical data for past 10 years.

Interactive Chart of Research and Development Expense of Revenue of NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 1.07% 1.31% 1.07%
2021 0.3% 0.54% 0.98% 0.28% 0.52%
2020 1.91% 5.76% 2.89% 0.48% 2.87%
2019 1.06% 3.03% 1.79% 5.7% 2.79%
2018 2.95% 1.43% 2.18% 1.56% 2.07%
2017 2.31% 3.23% 1.7% 1.68% 2.25%
2016 3.83% 0.12% 10.44% 54.28% 11.52%
2015 74.92% 130.25% 134.62% 294.24% 130.75%
2014 485.74% 1521.05% 1819.51% 884.72% 899.72%
2013 801.18% 228.66% 346.34% 286.76% 358.38%
2012 190.22% 69.03% 273.02% 171.52% 133.51%
2011 178.78% 89.94%

Business Profile of NovaBay Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology